We read with interest two recent related case reports regarding false potassium results in patients with very high white cell counts. 1, 2 In our laboratory, we have also seen both pseudohyperkalaemia and pseudohypokalaemia in the presence of major leukocytosis. In 2004, we reported a study in seven leukaemic children with white cell counts .300 Â 10 9 /L. 3 In four of these, the plasma potassium concentrations, measured after vacuum tube transport and centrifugation, were markedly higher than corresponding plasma potassium concentrations measured on a blood gas machine within 60 min of the samples being taken. For example, one patient with a white cell count of 812 Â 10 9 /L had a plasma potassium concentration of 9.8 mmol/L after centrifugation with a corresponding potassium concentration measured using whole blood of 4.0 mmol/L. In 2006, we reported pseudohypokalaemia in a boy with myeloid leukaemia and a white cell count .200 Â 10 9 /L. 4 His centrifuged plasma potassium results were 1.4 and 1.2 mmol/L, with corresponding potassium concentrations measured using whole blood of 3.0 and 4.1 mmol/ L. He had a marked metabolic alkalosis, so potassium may have moved into his white cells ex vivo at room temperature before his blood was centrifuged.
Effect of non-glucose sugars and haematocrit on glucose measurements with Roche Accu-Chek Performa glucose strips
Point-of-care blood glucose meters based on glucose dehydrogenase (GDH) and pyrroloquinoline quinone (PQQ)-coupled reaction are subject to interference by nonglucose sugars 1 and icodextrin metabolites, chiefly maltose. 2 Reports of treatment of spurious hyperglycaemia, arising from the interference, with insulin leading to lifethreatening/fatal hypoglycaemia caused the Food and Drug Administration and others 3 -6 to issue safety notices to alert health professionals of the dangers of using GDH-PQQ-based glucose monitoring systems.
Roche Accu-Chek Advantage/Sensor Comfort glucose test strip (Roche Diagnostics, Basle, Switzerland) is based on GDH-PQQ reaction and is subject to positive interference by the non-glucose sugars mentioned in the safety notices.
Roche has now launched a successor glucose test strip called Accu-Chek Performa. Although the latter is still based on GDH-PQQ reaction, it is claimed that maltose interference has been eliminated and that blood glucose results are not significantly influenced by patients' haematocrit within the range of 10 -65%.
We evaluated the Performa glucose test strips for interference from non-glucose sugars (fructose, galactose, lactose, maltose, mannose and xylose) and for the effect of blood haematocrit on blood glucose measurements. Throughout this study, glucose metabolism in heparinized whole venous blood was inhibited by adding DL-glyceraldehyde to a final concentration of 10 mmol/L 7 and glucose results were reported as concentration of glucose in plasma. 8 For the interference study, heparinized venous blood containing 10 mmol/L DL-glyceraldehyde was spiked with solution of non-glucose sugar to achieve the final concentrations of 0, 2.5, 5.0, 10.0, 15.0 and 20 mmol/L. The basal blood glucose concentration in these experiments was 5.2 mmol/L. After roller-mixing for 15 min at room temperature, glucose concentrations were determined with 
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